Moreover, sex hormones, in females, have a direct effect on drug absorption, distribution, metabolism, elimination and adverse effects [43].This study implies that sex-specific drug dosing regimens may be warranted for treatment of neurological diseases that affect the blood brain barrier, including CLN3 disease in mouse and man. The gene discussed is CLN3; the disease is glycogen storage disease VI.